— RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial
August 26, 2026
• 2 min read
The FDA approved the first-in-class RAS inhibitor daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer.
The approval stipulates use in adults with PDAC previously treated with at least one prior systemic regimen or that is ineligible for multiagent systemic therapy. The oral drug targets multiple isoforms of RAS, a driver mutation for most patients with PDAC.
